International Journal of Molecular Sciences · 2020 · 572 citations · 42 references
Life SciencesImmunologyPharmacologyEndocytosisInnate ImmunityMembrane TraffickingBlood-brain Barrier BiologyBlood-brain Barrier DeliveryBlood-brain Barrier PenetrationCellular UptakeBlood-brain Barrier PermeabilityBlood-brain Barrier TraffickingExosomesExtracellular VesiclesInflammation-mediated Bbb TransportPharmacokinetics At The Blood-brain BarrierTranscytosis Across The Blood-brain BarrierTranscytosis At The Blood-brain Barrier
Extracellular vesicles can cross the blood-brain barrier (BBB), but little is known about passage. Here, we used multiple-time regression analysis to examine the ability of 10 exosome populations derived from mouse, human, cancerous, and non-cancerous cell lines to cross the BBB. All crossed the BBB, but rates varied over 10-fold. Lipopolysaccharide (LPS), an activator of the innate immune system, enhanced uptake independently of BBB disruption for six exosomes and decreased uptake for one. Wheatgerm agglutinin (WGA) modulated transport of five exosome populations, suggesting passage by adsorptive transcytosis. Mannose 6-phosphate inhibited uptake of J774A.1, demonstrating that its BBB transporter is the mannose 6-phosphate receptor. Uptake rates, patterns, and effects of LPS or WGA were not predicted by exosome source (mouse vs. human) or cancer status of the cell lines. The cell surface proteins CD46, AVβ6, AVβ3, and ICAM-1 were variably expressed but not predictive of transport rate nor responses to LPS or WGA. A brain-to-blood efflux mechanism variably affected CNS retention and explains how CNS-derived exosomes enter blood. In summary, all exosomes tested here readily crossed the BBB, but at varying rates and by a variety of vesicular-mediated mechanisms involving specific transporters, adsorptive transcytosis, and a brain-to-blood efflux system.
42
Clotilde Théry, Kenneth W. Witwer, Elena Aïkawa et al. · Journal of Extracellular Vesicles · 2018 · 11.2K citations · Full text
Exosomes as drug delivery vehicles for Parkinson's disease therapy
Matthew J. Haney, Natalia L. Klyachko, Yuling Zhao et al. · Journal of Controlled Release · 2015 · 2K citations · Full text
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Min Shi, Changqin Liu, Travis J. Cook et al. · Acta Neuropathologica · 2014 · 675 citations